Patient Deaths Stop Infinity Pharma's Phase III HSP90 Trial In Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Infinity Pharmaceuticals' decision to pull the plug on the registrational Phase III trial with heat shock protein 90 inhibitor IPI-504 - the only product not part of the broad-ranging deal with affiliated specialty pharmas Purdue and Mundipharma - put a chill into investors April 15
You may also be interested in...
Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.
In exchange for ex-U.S. rights to the bulk of its early-stage oncology pipeline, Infinity has secured a cash runway into 2013.
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf